Expanding Our Mechanistic Understanding for the Role of the Microbiome in Immuno- Oncology
Time: 11:45 am
day: Day 1 Track A AM
Details:
- Advancing two consortia into the clinic: MB310 in ulcerative colitis and MB097 in advanced melanoma with pembrolizuma
- Selecting of strains comprising each consortium were due to strong associations with positive outcomes in clinical trials rather than mechanism
- Exploring translational data which demonstrates the multiple mechanisms by which these bacteria impact host responses linked to disease pathology
